Gary Peters wants you to know he's working hard on automotive safety. Good for him. While he was doing that, he was also selling Corteva Agriscience, buying J.M. Smucker, and picking up a 5K-to-$50K position in PepsiCo, all on the same day, all while sitting on the Senate Appropriations subcommittee that funds the FDA and related food and agriculture agencies. The automotive bill is fine. The food-and-beverage shopping spree is the part worth a second look.
The News Hook
Peters introduced a bipartisan bill this week to accelerate testing and deployment of automotive safety technologies. It's the kind of legislation that generates a press release, a quote about Michigan jobs, and a brief item in the Alpena News. Peters sits on the Senate Commerce, Science, and Transportation Committee, specifically the Surface Transportation, Freight, Pipelines, and Safety subcommittee, so pushing an auto-safety bill is exactly what he's supposed to be doing. Constituent service. Fine.
What's less routine is what Peters filed with the clerk on April 23.
Three Trades, One Day, One Interesting Sector
On April 23, 2026, Peters disclosed three transactions. He sold Corteva Agriscience (CTVA) in the 5K-to-$50K range. He bought J.M. Smucker (SJM) in the K-to-5K range. And he bought PepsiCo (PEP) in the 5K-to-$50K range.
Smucker makes Jif peanut butter and Folgers coffee. PepsiCo makes Lay's, Gatorade, Quaker Oats, and, yes, Pepsi. These are consumer packaged goods companies. Food and beverage. The FDA's jurisdiction.
Peters sits on the Senate Appropriations subcommittee covering Agriculture, Rural Development, Food and Drug Administration, and Related Agencies. That's not a tangential overlap. The subcommittee he serves on writes the checks for the agency that regulates the sector he just bought into.
Per his full disclosure record on Blind Trust, the PepsiCo buy is flagged as a committee overlap trade. Thirty days out, the alpha on that position is a modest +0.4% versus the S&P 500, not a windfall, but not irrelevant. The overlap is the story, not the return.
The Corteva Sale Is Its Own Thing
Corteva is an agricultural chemicals and seeds company, the kind of business that falls squarely under the Agriculture appropriations portfolio Peters helps oversee. He sold 5K-to-$50K worth of it on April 23. Thirty days later, that sale had generated -5.6% alpha versus the S&P 500, meaning the stock underperformed the market after he got out.
That's also a committee overlap trade. He was sitting on the subcommittee that funds agricultural programs, and he was selling a major agricultural inputs company. The filing is public. The committee assignment is public. The calendar is public.
There are no flagged vote-trade overlaps in this data, no specific vote immediately before or after these trades that lines up in a way that demands attention. What there is, instead, is a quieter and more structural question: when you write the appropriations language for the FDA and the USDA, and you're also actively trading the stocks of companies those agencies regulate, the conflict doesn't require a smoking gun. The architecture is the issue.
The Alpha Record, Honestly
Peters has nine scored trades in the full sample. Five finished positive. Four finished negative. His mean 30-day alpha across the full sample sits at -3.4% versus the S&P 500. That's a senator who, on balance, has been a slightly worse stock picker than just owning an index fund.
The best trades in the sample: a January 2026 purchase of Stanley Black and Decker (SWK) at +9.2% alpha, a January 2026 purchase of W. P. Carey (WPC) at +7.3%, and a November 2025 buy of Conagra Brands (CAG) at +3.8%. None of those three carry a committee overlap flag. They're just trades that happened to work out.
The worst: the CTVA sale at -5.6%, an Intel (INTC) sale in December 2025 at -5.8%, and an Organon (OGN) sale in October 2025 at a brutal -39.9% alpha. The Intel sale carries a committee overlap flag, Peters sits on the Commerce subcommittee covering Science, Manufacturing, and Competitiveness, which has oversight reach into semiconductor policy. He sold Intel in December 2025. The stock then significantly underperformed the market over the following 30 days.
Five wins and four losses, mean return in the red. If there's an edge here, it's not showing up in the aggregate.
The Automotive Bill and the Food Portfolio
The juxtaposition is almost too clean. Peters is in the news for a bipartisan automotive safety push, a bill within his actual surface transportation remit, a clean legislative story, good optics. And on the same day he filed the April 23 trades, he was loading up on companies that make chips, crackers, and flavored beverages.
The automotive bill won't move Pepsi's stock price. The FDA's regulatory posture toward food labeling, PFAS in packaging, or dietary supplement rules absolutely could. Peters doesn't set that policy unilaterally, no single senator does, but the Appropriations subcommittee he sits on shapes the FDA's budget and, by extension, its enforcement capacity.
Members are required to disclose. They are not required to divest, recuse, abstain, or explain themselves. That's the rule. Yes, really.
The Votes
Peters's recent floor votes don't generate a direct overlap angle here. He voted yes on a motion to proceed on a joint resolution disapproving an EPA rule on hazardous air pollutant standards for coal and oil-fired power plants, the motion failed on June 3. He voted yes twice on motions related to directing the removal of U.S. Armed forces from hostilities with Iran. He voted against the Secure America Act when it passed on June 5.
None of those votes map directly to his food-and-beverage trades. The EPA vote touches energy policy, not his Appropriations subcommittees. The Iran votes are pure national security floor business. The Secure America Act is immigration. Floor votes are floor votes, every senator casts them on bills far outside their committee jurisdiction, and the brief requires us to be precise about this: a floor vote is only a conflict angle when the bill subject falls inside a member's actual committee remit. These don't.
The conflict angle here lives entirely in the committee overlap trades: PepsiCo, Corteva, and Intel. Three trades, three flagged overlaps, across two committee jurisdictions Peters actively serves.
What the Filing Says
The April 23 cluster is the freshest data point. A PepsiCo purchase, a J.M. Smucker purchase, and a Corteva sale, all on one day, all in sectors adjacent to Peters's Appropriations subcommittee work. The Smucker buy doesn't appear in the formal committee overlap list, but Smucker is a food company, and Peters appropriates for the FDA. Draw your own Venn diagram.
The prior committee overlap trades fill out the picture. In December 2025, he bought Verizon (VZ), a telecom, while sitting on the Commerce subcommittee covering Telecommunications and Media. That trade produced -1.4% alpha over 30 days. Also in December 2025, he sold Intel while sitting on the Science, Manufacturing, and Competitiveness subcommittee. That produced -5.8% alpha. So the committee overlap trades, taken together: mixed to negative returns, consistent sector overlap.
The receipts are public. Make of them what you make of them.